Free Content Inhibiting matrix metalloproteinase by cell-based TIMP-3 gene transfer effectively treats acute and chronic ischemic cardiomyopathy

Authors: Hai Tian, Ming-Li Huang, Kai-Yu Liu, Zhi-Bo Jia, Lu Sun, Shu-Lin Jiang, Wei Liu, Heather Y. McDonald Kinkaid, Jun Wu, Ren-Ke Li

Source: Cell Transplantation

Publisher: Cognizant Communication Corporation

Buy & download fulltext article:

Free content The full text is free.
View now:
PDF

Abstract:

Aims: After a myocardial infarction (MI), an increase in the cardiac ratio of matrix metalloproteinases (MMPs) relative to their inhibitors (TIMPs) causes extracellular matrix modulation that leads to ventricular dilatation and congestive heart failure. Cell therapy can mitigate these effects. In this study, we tested whether increasing MMP inhibition via cell-based gene transfer of Timp-3 further preserved ventricular morphometry and cardiac function in a rat model of MI. We also measured the effect of treatment timing. Methods: We generated MI (coronary artery ligation) in adult rats. Three or 14 days later, we implanted medium (control) or vascular smooth muscle cells transfected with empty vector (VSMCs) or Timp-3 (C-TIMP-3) into the peri-infarct region (n=15—24/group). We assessed MMP-2 and -9 expression and activity, TIMP-3 and TNF-α expression, cell apoptosis, infarct size and thickness, ventricular morphometry, and cardiac function (by echocardiography). Results: Relative to medium, VSMCs delivered at either time point significantly reduced cardiac expression and activity of MMP-2 and -9, reduced expression of TNF-α, and increased expression of TIMP-3. Cell therapy also reduced apoptosis and scar area, increased infarct thickness, preserved ventricular structure, and reduced functional loss. All these effects were augmented by C-TIMP-3 treatment. Survival and cardiac function were significantly greater when VSMCs or C-TIMP-3 were delivered at 3 (vs. 14) days after MI. Conclusions: Upregulating post-MI cardiac TIMP-3 expression via cellbased gene therapy contributed additional regulation of MMP, TIMP, and TNF-α levels, thereby boosting the structural and functional effects of VSMCs transplanted at 3 or 14 days after an MI in rats. Early treatment may be superior to late, though both are effective.

Document Type:

DOI: http://dx.doi.org/10.3727/096368911X601000

Appeared or available online: September 23, 2011

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page